From: Association between β-blocker use and mortality in critically ill patients: a nested cohort study
180 Day Mortality | ICU Mortality | Hospital Mortality | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Variable | N | aOR | 95% CI | P value for interaction | N | aOR | 95% CI | P value for interaction | N | aOR | 95% CI | P value for interaction |
Age (years) | ||||||||||||
Age < 58 | 230 | 0.57 | 0.10–3.2 | 0.58 | 263 | 1.89 | 0.56–6.4 | 0.43 | 263 | 1.21 | 0.41–3.5 | 0.27 |
Age > 58 | 247 | 0.83 | 0.43–1.62 | 260 | 1.48 | 0.72–3.1 | 260 | 1.11 | 0.62–1.99 | |||
Gender | ||||||||||||
Male | 355 | 0.54 | 0.23–1.26 | 0.57 | 391 | 1.72 | 0.80–3.68 | 0.14 | 391 | 0.95 | 0.49–1.85 | 0.82 |
Female | 122 | 1.45 | 0.52–4.1 | 132 | 1.30 | 0.44–3.88 | 132 | 1.45 | 0.62–3.39 | |||
Diabetes | ||||||||||||
Yes | 194 | 0.63 | 0.30–1.36 | 0.07 | 208 | 0.93 | 0.40–2.17 | 0.01 | 208 | 0.73 | 0.39–1.38 | 0.002 |
No | 283 | 1.22 | 0.40–3.7 | 315 | 2.93 | 1.19–7.23 | 315 | 2.43 | 1.05–5.64 | |||
Vasopressors | ||||||||||||
Yes | 307 | 0.70 | 0.32–1.50 | 0.36 | 341 | 1.86 | 0.89–3.89 | 0.85 | 341 | 1.25 | 0.67–2.32 | 0.84 |
No | 170 | 1.10 | 0.32–3.74 | 182 | 0.89 | 0.27–2.99 | 182 | 0.83 | 0.32–2.18 | |||
APACHE II score | ||||||||||||
< 23 | 236 | 0.85 | 0.22–3.26 | 0.32 | 271 | 2.22 | 0.66–7.48 | 0.12 | 271 | 1.12 | 0.40–3.13 | 0.23 |
> 23 | 241 | 0.67 | 0.32–1.40 | 252 | 1.23 | 0.59–2.56 | 252 | 0.98 | 0.53–1.82 | |||
Sepsis | ||||||||||||
Yes | 117 | 0.83 | 0.24–2.95 | 0.37 | 122 | 1.06 | 0.30–3.78 | 0.12 | 122 | 0.92 | 0.32–2.63 | 0.06 |
No | 360 | 0.71 | 0.33–1.51 | 401 | 1.91 | 0.90–4.08 | 401 | 1.26 | 0.70–2.37 | |||
Severe sepsis | ||||||||||||
Yes | 115 | 0.52 | 0.11–2.41 | 0.71 | 125 | 0.73 | 0.25–2.09 | 0.19 | 125 | 0.71 | 0.25–2.01 | 0.72 |
No | 362 | 0.80 | 0.39–1.62 | 398 | 2.09 | 092–4.73 | 398 | 1.10 | 0.59–2.06 | |||
Admission category | ||||||||||||
Non-operative | 404 | 0.79 | 0.41–1.52 | 0.92 | 435 | 1.50 | 0.78–2.90 | 0.50 | 435 | 1.15 | 0.67–1.98 | 0.81 |
Post-operative | 73 | 0.21 | 0.015–3.0 | 88 | 1.96 | 0.26–14.71 | 88 | 0.52 | 0.09–3.06 | |||
Chronic Respiratory Disease | ||||||||||||
Yes | 68 | 1.15 | 0.21–6.32 | 0.85 | 70 | 4.89 | 1.18–20.30 | 0.11 | 70 | 7.27 | 1.39–37.93 | 0.06 |
No | 409 | 0.62 | 0.30, 1.26 | 453 | 1.28 | 0.61–2.71 | 453 | 0.80 | 0.44–1.43 | |||
Chronic Renal disease | ||||||||||||
Yes | 53 | 1.22 | 0.33–4.5 | 0.97 | 55 | 1.39 | 0.29–6.63 | 0.69 | 55 | 0.82 | 0.24–2.77 | 0.25 |
No | 424 | 0.60 | 0.28–1.27 | 468 | 1.55 | 0.78–3.09 | 468 | 1.10 | 0.62–1.96 | |||
Chronic Cardiac disease | ||||||||||||
Yes | 74 | 0.56 | 0.18–1.71 | 0.13 | 77 | 0.69 | 0.19–2.48 | 0.09 | 77 | 0.45 | 0.16–1.29 | 0.003 |
No | 403 | 0.75 | 0.34–1.64 | 446 | 1.88 | 0.92–3.85 | 446 | 1.34 | 0.74–2.44 | |||
Estimated GFR (mL/min) | ||||||||||||
≤ 73 | 246 | 0.82 | 0.42–1.62 | 0.23 | 261 | 1.02 | 0.50–2.05 | 0.08 | 261 | 0.84 | 0.47–1.50 | 0.06 |
> 73 | 231 | 0.21 | 0.03–1.54 | 262 | 3.40 | 0.89–12.89 | 262 | 1.36 | 0.44–4.25 | |||
SOFA score | ||||||||||||
≤ 9 | 274 | 0.70 | 0.26–1.84 | 0.56 | 305 | 1.39 | 0.51–3.79 | 0.99 | 305 | 0.89 | 0.40–1.97 | 0.90 |
> 9 | 203 | 0.77 | 0.31–1.85 | 218 | 1.62 | 0.71–3.68 | 218 | 1.29 | 0.61–2.73 | |||
ICU duration (days) | ||||||||||||
≤ 5 | 231 | 0.74 | 0.28–1.92 | 0.70 | 256 | 1.44 | 0.52–4.03 | 0.51 | 256 | 1.07 | 0.46–2.47 | 0.31 |
> 5 | 246 | 0.70 | 0.29–1.71 | 267 | 1.60 | 0.71–3.58 | 267 | 1.06 | 0.50–2.25 | |||
Statin Use | ||||||||||||
Yes | 66 | 0.92 | 0.30–2.79 | 0.86 | 68 | 0.46 | 0.10–2.10 | 0.02 | 68 | 1.005 | 0.35–2.92 | 0.19 |
No | 411 | 0.65 | 0.28–1.51 | 455 | 2.29 | 1.16–4.54 | 455 | 1.40 | 0.76–2.57 |